FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A fine of the seasons		00540
<i>N</i> ashington,	D.C.	20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours ner resnonse	. 05								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Name and Address of Departing Decon*				2. Is	2. Issuer Name <b>and</b> Ticker or Trading Symbol								5. R	5. Relationship of Reporting Person(s) to Issuer							
1. Name and Address of Reporting Person*  RIEDEL NORBERT G					Cerevel Therapeutics Holdings, Inc. [ CERE							(Che	(Check all applicable)								
- IttLD1	LIVOILD				. []	]								2	Directo			10% Ov			
(Last) (First) (Middle)						Date of Earliest Transaction (Month/Day/Year)								below)	(give title		Other (s below)	pecify			
C/O CEREVEL THERAPEUTICS HOLDINGS,					06/0	06/07/2023															
INC.					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. In	6. Individual or Joint/Group Filing (Check Applicable						
222 JACOBS STREET, SUITE 200						, , , , , , , , , , , , , , , , , , , ,								- 1	Line)						
															X Form filed by One Reporting Person  Form filed by More than One Reporting						
(Street)						Form filed by More Person											e mai	т Опе керо	rung		
CAMBR	CAMBRIDGE MA 02141			Bu	Dula 10hE 1(a) Transaction Indication																
					.   ˈˈ\u	Rule 10b5-1(c) Transaction Indication															
(City)	(S	tate)	(Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to															
		<u> </u>	saus	siy the amin	mative	detense cor	iditior	ns of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Nor	ı-Deriv	ative	Se	curities	s Ac	quired, I	Disp	osed c	of, or B	ene	eficiall	y Owned	i					
1. Title of	Security (Ins	tr. 3)	1	2. Trans	action	Execution Date if any			3. 4. Securit										7. Nature		
				Date (Month/	Day/Yea				Code (In	Transaction Dis		ed Of (D) (Instr. 3, 4		3, 4 and	Benefici	ally (D)	(D) o	or Indirect   I	of Indirect Beneficial		
						-	(Month/Day/Yea		r) 8)	—					Reported	d i	(I) (Ir		Ownership (Instr. 4)		
										٧	Amount	(A)	or	Price	Transaci (Instr. 3						
Common Stock 06/07/2				7/2023	023 A 3,282 <sup>(1)</sup> A <sup>(1)</sup>		46,	46,092		D											
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
		•							, option						• · · · · · · · ·						
1. Title of	2.	3. Transaction	3A. Deeme		4.		5. Numl	ber	6. Date Exe	rcisa	ble and	7. Title a			8. Price of	9. Number		10.	11. Nature		
				Transac Code (Ir				Expiration Date Amount of (Month/Day/Year) Securities					Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial				
(Instr. 3) Price of Derivative (Month/Day/Year) 8							Securities Acquired		s \ Underlying					ecurity	(Instr. 5)	Beneficially Owned		Direct (D) or Indirect	Ownership (Instr. 4)		
	Security		(A) or (Instr. 3 and 4)								Following Reported		(I) (Instr. 4)	(,							
				of (D) (Instr. 3, 4								Transaction(s)									
								and 5)									(111301. 4)				
													Ai	mount							
									Date	_	xpiration			umber							
					Code	v	(A)	(D)	Exercisable		ate	Title		hares							
Stock																					
Option (Right to Buy)	\$32.6	06/07/2023			A		13,780		(2)	06	5/07/2033	Stock		3,780	\$0.00	13,780	)	D			

## Explanation of Responses:

- 1. The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.
- 2. 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.

## Remarks:

<u>/s/ Mark Bodenrader, as</u> <u>Attorney-in-Fact</u> <u>06/09/2023</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.